Patents by Inventor Tae-Bo Sim

Tae-Bo Sim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180065969
    Abstract: The present invention provides a therapeutic agent of acute myeloid leukemia containing a 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-d]pyrimidine-2(1H)-one compound as an active ingredient, which has proliferation inhibitory activity for a human acute myeloid leukemia cell line OCI-AML3 having a NRAS mutant gene while having low inhibitory activity for wild type NRAS and has activity of inhibiting GCK and ACK1 protein kinases at the same time.
    Type: Application
    Filed: August 9, 2017
    Publication date: March 8, 2018
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo SIM, Han Na CHO, Eun Hye JU, Woo Young HUR, Ho Jong YOON, Chi Man SONG
  • Publication number: 20180065970
    Abstract: The present invention provides a pharmaceutical composition, as an effective ingredient, a urea compound having a protein kinase inhibitory activity and containing a 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one skeleton, and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 10, 2017
    Publication date: March 8, 2018
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo SIM, Woo Young HUR, Ho Jong YOON, Chi Man SONG, Eun Hye JU, Han na CHO, Hwan Geun CHOI
  • Publication number: 20180050036
    Abstract: The present invention relates to a therapeutic agent for chronic myelogenous leukemia with reduced drug-resistance and side-effects containing a 1,6-disubstituted indole compound.
    Type: Application
    Filed: August 15, 2017
    Publication date: February 22, 2018
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo SIM, Ho Jong YOON, Woo Young HUR, Yun Ju NAM, Hwan Geun CHOI
  • Patent number: 9586936
    Abstract: A heteroarylamine compound includes protein kinase inhibition activity, a pharmaceutically acceptable salt thereof and a pharmaceutical composition for preventing and treating a disease caused by abnormal cell growth, which contains the compound as an active ingredient.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: March 7, 2017
    Assignee: KOREA INSTITITUE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo Sim, Ho Jong Yoon, Ji Hye Yoon, Woo Young Hur, Eun Joo Roh, Yeon Ui Kwak
  • Patent number: 9422307
    Abstract: A substituted thieno pyrimidine compound of Formula 1, pharmaceutically acceptable salts and a pharmaceutical composition thereof is provided. The compound of Formula 1 exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction. The compound of Formula 1 and its compositions are useful for the prevention and treatment of diseases caused by abnormal cell growth including cancer.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: August 23, 2016
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo Sim, Jung Mi Hah, Hwan Geun Choi, Young Jin Ham, Jung Hun Lee, Dong Sik Park, Hwan Kim
  • Publication number: 20160145240
    Abstract: A heteroarylamine compound includes protein kinase inhibition activity, a pharmaceutically acceptable salt thereof and a pharmaceutical composition for preventing and treating a disease caused by abnormal cell growth, which contains the compound as an active ingredient.
    Type: Application
    Filed: November 20, 2015
    Publication date: May 26, 2016
    Inventors: Tae Bo SIM, Ho Jong YOON, Ji Hye YOON, Woo Young HUR, Eun Joo ROH, Yeon Ui KWAK
  • Patent number: 8999973
    Abstract: The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: April 7, 2015
    Assignees: Hanmi Science Co., Ltd, Korea Institute of Science and Technology, Catholic University Industry Academic Cooperation Foundation
    Inventors: Jung Beom Son, Seung Hyun Jung, Wha II Choi, Young Hee Jung, Jae Yul Choi, Ji Yeon Song, Kyu Hang Lee, Jae Chul Lee, Eun Young Kim, Young Gil Ahn, Maeng Sup Kim, Hwan Geun Choi, Tae Bo Sim, Young Jin Ham, Dong-sik Park, Hwan Kim, Dong-Wook Kim
  • Patent number: 8871950
    Abstract: The present invention relates to a method for preparing (+)-polyoxamic acid and a novel intermediate compound synthesized during preparation thereof. The preparation method according to the present invention allows preparation of (+)-polyoxamic acid with high optical purity in high yield. In particular, the preparation method is useful for mass production because the process is simple.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: October 28, 2014
    Assignee: Korea Institute of Science and Technology (KIST)
    Inventors: Tae Bo Sim, Ho Jong Yoon, Eun Joo Roh
  • Patent number: 8765749
    Abstract: Disclosed are a 1,6-substituted indole compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of cancers caused by abnormal cell growth comprising the compound as an effective ingredient. Since the novel indole compound exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating cancers caused by abnormal cell growth.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: July 1, 2014
    Assignee: Korea Institute of Science and Technology
    Inventors: Tae Bo Sim, Young Jin Ham, Kyung Ho Yoo, Chang Hyun Oh, Jung Mi Hah, Hwan Geun Choi, Hwan Kim, Eun Jin Jun
  • Patent number: 8754209
    Abstract: Disclosed are novel indazole derivatives represented by the following Chemical Formula 1 or pharmaceutically acceptable salts, hydrates or solvates thereof, and pharmaceutical compositions for the prevention or treatment of proliferative diseases, containing the same as an active ingredient. Having potent inhibitory effect against protein kinase, such as b-raf, KDR, Fms, Tie2, SAPK2a and Ret, inducing diseases caused by abnormal cell proliferation, the novel indazole derivatives can be used for the prevention or treatment of diseases caused by abnormal cell proliferation.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: June 17, 2014
    Assignees: Korea Institute of Science and Technology, Korea Research Institute of Chemical Technology, Korea Research Institute of Bioscience and Biotechnology
    Inventors: Tae Bo Sim, Jung Beom Son, Hwan Kim, Dong Sik Park, Hwan Geun Choi, Young Jin Ham, Jung Mi Hah, Kyung Ho Yoo, Chang Hyun Oh, So Ha Lee, Jae Du Ha, Sung Yun Cho, Byoung Mog Kwon, Dong Cho Han
  • Publication number: 20140155635
    Abstract: Disclosed are a novel resorcyclic acid lactone compound with inhibitory activity against protein kinases, a pharmaceutically acceptable salt thereof, a method for the synthesis thereof, and a pharmaceutical composition for the treatment and prevention of various cancer diseases comprising the same as an active ingredient. The novel resorcyclic acid lactone compound is useful as a therapeutic for cancer diseases, especially blood cancer, inter alia, acute myeloid leukemia (AML).
    Type: Application
    Filed: October 29, 2013
    Publication date: June 5, 2014
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo SIM, Ho Jong Yoon, Ji Nyeo Kim
  • Publication number: 20140148606
    Abstract: Disclosed is a methyl violet derivative having inhibitory activity against allosteric focal adhesion kinase (FAK) and is useful as an agent for preventing or treating cancer.
    Type: Application
    Filed: October 29, 2013
    Publication date: May 29, 2014
    Applicant: Korea Institute of Science and Technology
    Inventors: Tae Bo SIM, Hwan KIM
  • Patent number: 8648089
    Abstract: Disclosed are a 1,3,6-substituted indole compound having inhibitory activity for protein kinases, a pharmaceutically acceptable thereof, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth including the compound as an active ingredient. Since the novel indole compound exhibits superior inhibitory activity for various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating cancers caused by abnormal cell growth.
    Type: Grant
    Filed: November 24, 2012
    Date of Patent: February 11, 2014
    Assignee: Korea Institute of Science and Technology
    Inventors: Tae Bo Sim, Young Jin Ham, Hwan Geun Choi
  • Patent number: 8586580
    Abstract: Disclosed are a 2,7-substituted thieno[3,2-d]pyrimidine compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth comprising the compound as an effective ingredient. Since the novel 2,7-substituted thieno[3,2-d]pyrimidine compound exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating diseases caused by abnormal cell growth.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: November 19, 2013
    Assignee: Korea Institute of Science and Technology
    Inventors: Tae Bo Sim, Hwan Geun Choi, Jung Mi Hah, Young Jin Ham, Eun Jin Jun, Jung Hun Lee, Hwan Kim
  • Publication number: 20130053370
    Abstract: The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.
    Type: Application
    Filed: January 31, 2011
    Publication date: February 28, 2013
    Applicants: HANMI SCIENCE CO., LTD., CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Jung Beom Son, Seung Hyun Jung, Wha ll Choi, Young Hee Jung, Jae Yul Choi, Ji Yeon Song, Kyu Hang Lee, Jae Chul Lee, Eun Young Kim, Young Gil Ahn, Maeng Sup Kim, Hwan Geun Choi, Tae Bo Sim, Young Jin Ham, Dong-sik Park, Hwan Kim, Dong-Wook Kim
  • Publication number: 20130012703
    Abstract: Disclosed are a 2,4,7-substituted thieno[3,2-d]pyrimidine compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth comprising the compound as an effective ingredient. Since the novel 2,4,7-substituted thieno[3,2-d]pyrimidine compound exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating diseases caused by abnormal cell growth.
    Type: Application
    Filed: October 22, 2010
    Publication date: January 10, 2013
    Inventors: Tae Bo Sim, Jung Mi Hah, Hwan Geun Choi, Young Jin Ham, Jung Hun Lee, Dong Sik Park, Hwan Kim
  • Patent number: 8329708
    Abstract: Disclosed are a 1,3,6-substituted indole compound having inhibitory activity for protein kinases, a pharmaceutically acceptable thereof, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth including the compound as an active ingredient. Since the novel indole compound exhibits superior inhibitory activity for various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating cancers caused by abnormal cell growth.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: December 11, 2012
    Assignee: Korea Institute of Science and Technology
    Inventors: Tae Bo Sim, Young Jin Ham, Kyung Ho Yoo, Chang Hyun Oh, Jung Mi Hah, Hwan Kim, Hwan Geun Choi, Jung-Hun Lee
  • Publication number: 20120302567
    Abstract: The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.
    Type: Application
    Filed: January 28, 2011
    Publication date: November 29, 2012
    Applicants: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, HANMI PHARM. CO. LTD.
    Inventors: Seung Hyun Jung, Young Hee Jung, Wha Il Choi, Jung Beom Son, Eun Ju Jeon, In Ho Yang, Tae Hun Song, Mi Kyoung Lee, Myoung Sil Ko, Young Gil Ahn, Maeng Sup Kim, Young Jin Ham, Tae Bo Sim, Hwan Geun Choi, Jung Mi Han, Dong-sik Park, Hwan Kim
  • Publication number: 20120277424
    Abstract: Disclosed are a 2,7-substituted thieno[3,2-d]pyrimidine compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth comprising the compound as an effective ingredient. Since the novel 2,7-substituted thieno[3,2-d]pyrimidine compound exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating diseases caused by abnormal cell growth.
    Type: Application
    Filed: October 15, 2010
    Publication date: November 1, 2012
    Applicant: Korea Institute of Science and Technology
    Inventors: Tae Bo Sim, Hwan Geun Choi, Jung Mi Hah, Young Jin Ham, Eun Jin Jun, Jung Hun Lee, Hwan Kim
  • Publication number: 20120271048
    Abstract: Disclosed are a 1,6-substituted indole compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of cancers caused by abnormal cell growth comprising the compound as an effective ingredient. Since the novel indole compound exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating cancers caused by abnormal cell growth.
    Type: Application
    Filed: October 20, 2010
    Publication date: October 25, 2012
    Applicant: Korea Institute of Science and Technology
    Inventors: Tae Bo Sim, Young Jin Ham, Kyung Ho Yoo, Chang Hyun Oh, Jung Mi Hah, Hwan Geun Choi, Hwan Kim, Eun Jin Jun